The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall...
See more from Akiva Diamond
Large European retrospective analysis of 3700 patients >=70 with leukemia showed median OS of 10.9 months with high intensity treatment vs 9.2 months with HMA. Early mortality was significantly higher (6.8%, n=116) in the high intensity treated patients. Survival significantly splits at 3 and 5 years.